Advertisement

Search Results

Advertisement



Your search for ,foR matches 32821 pages

Showing 17051 - 17100


lung cancer
immunotherapy

FDA Expands Approval of Pembrolizumab for First-Line Treatment of NSCLC

The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to the immune checkpoint inhibitor pembrolizumab (Keytruda) for use in combination with chemotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC). KEYNOTE-021 This...

leukemia

Quizartinib in Relapsed or Refractory AML

In a phase II trial reported in The Lancet Oncology, Cortes et al found that the next-generation FLT3 inhibitor quizartinib had good activity in patients with relapsed or refractory acute myeloid leukemia (AML), with greater activity in patients with FLT3-ITD mutations. Study Details The study...

breast cancer

Long-Term Results of Adjuvant Endocrine Therapy in Premenopausal Breast Cancer

In an analysis of long-term outcomes in the SOFT and TEXT trials reported at the 2018 ASCO Annual Meeting and in The New England Journal of Medicine, Francis et al found that the addition of ovarian suppression to adjuvant tamoxifen significantly improved 8-year rates of disease-free and overall...

Inside Story on the Genesis of Teen Cancer America

THANK YOU for publishing the excellent article “We Need to Fill the Gap Between Pediatric and Adult Oncology Care” by Sarah Stream (as told to Jo Cavallo) in the March 25, 2018, issue of The ASCO Post. Sarah’s story and her connection to Teen Cancer America actually go much deeper than she reported ...

gynecologic cancers

FDA Approves Bevacizumab in Combination With Chemotherapy for Ovarian Cancer

ON JUNE 13, 2018, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) for the treatment of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV...

gynecologic cancers
lymphoma

Pembrolizumab Receives FDA Approval for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma, Advanced Cervical Cancer

THE U.S. FOOD and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma or who have relapsed after two or more prior lines of therapy on June 13, 2018. The newest ...

prostate cancer

Bipolar Androgen Therapy After Disease Progression in Metastatic Castration-Resistant Prostate Cancer

In a single-center phase II study reported in The Lancet Oncology, Teply et al found that bipolar androgen therapy can induce prostate-specific antigen (PSA) response and resensitization to enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer whose disease progressed on ...

issues in oncology

California Trends in Cancer Survival by Health Insurance Status

A study using California Cancer Registry data showed that survival improvements in patients with cancer between 1997 and 2014 have largely been limited to those with private or Medicare insurance. These findings were reported in JAMA Oncology by Libby Ellis, PhD, of the Cancer Prevention Institute...

cns cancers

Addition of Tumor-Treating Fields to Maintenance Temozolomide in Glioblastoma

The final results of a phase III trial reported by Roger Stupp, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and colleagues in JAMA indicate that adding antimitotic treatment with tumor-treating fields to maintenance temozolomide is associated with improved...

Endangered Art of Medicine

I hold a cold, lifeless mouse instead of my patient’s heated hand, checking off the tiny box marked “Anxiety,” while she squirms under twisted blankets.  I don’t remember when or how or why it happened, that the static screen wedged itself between my patients and me and compliance with the digital...

lymphoma

I’m Proud to Have Contributed to the FDA Approval of CAR T-Cell Therapy

When I was diagnosed with diffuse large B-cell lymphoma (DLBCL) in 2013, I used to joke that if I had to get cancer, this wasn’t a bad one to have. At just 32, I was otherwise healthy, and my prognosis for a cure was good, according to my oncologist. So I felt confident that once I underwent...

Colorectal Cancer Alliance Announces Available Research Funding

THE COLORECTAL CANCER Alliance has announced up to $775,000 in available funding for up to five grants supporting research in young-onset colorectal cancer, rectal cancer, and colorectal cancer prevention. The Colorectal Cancer Alliance is committed to investing $10 million in research by 2021,...

WHO Names St. Jude Its First Collaborating Center for Childhood Cancer

THE WORLD HEALTH ORGANIZATION (WHO) has designated St. Jude Children’s Research Hospital as the first WHO Collaborating Center for Childhood Cancer. With this collaboration, both organizations aim to expand efforts to develop strategies to strengthen the global resources, organization, and planning ...

lung cancer

Disparities Found in Lung Cancer Care, Survival in United States vs England

DESPITE STEADY declines in death rates in recent years, lung cancer remains the leading cause of cancer deaths in wealthy countries. In a study published by Anita Andreano, MD, of the University of Milan-Ciocco, and colleagues in the Journal of Thoracic Oncology,1 Yale researchers collaborated with ...

pancreatic cancer

Actively Recruiting Clinical Trials Focused on Pancreatic Cancer

THE INFORMATION contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on pancreatic cancer. These studies are investigating radiotherapy; cancer vaccines; combination treatments; novel cell therapies; response prediction; and more. All of the studies ...

issues in oncology
survivorship

Handheld Device for Detecting Heart Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer

Cardiovascular complications, such as anthracycline-related heart failure, are a leading cause of morbidity and mortality in survivors of childhood cancer, often developing at a time when these survivors are least engaged in long-term survivorship care, prompting the need for new paradigms in...

gynecologic cancers

FDA Grants Priority Review to Expanded Use of Gardasil 9 in Women and Men Aged 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases

On June 13, the U.S. Food and Drug Administration (FDA) accepted for review a new supplemental biologics license application (sBLA) for recombinant human papillomavirus (HPV) 9-valent vaccine (Gardasil  9). The application is seeking approval for an expanded age...

issues in oncology

Statement From FDA Commissioner on Agency Efforts to Advance the Patient Voice in Medical Product Development and Regulatory Decision-Making

U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, recently issued the following statement: Over the past decade, advances in our understanding of the basic biology of serious and life-threatening diseases has led to the development and FDA approval of targeted treatments for ...

colorectal cancer
cost of care

AMA Plans Advocacy Outreach to Expand Colorectal Screening

Building on the efficacy of colorectal cancer screening, the American Medical Association (AMA) endorsed a plan at its Annual Meeting to work with physicians and payers to make the screening more available and affordable. Challenges with insurance coverage remain a barrier to colorectal cancer...

lymphoma

Ibrutinib in Relapsed or Refractory Follicular Lymphoma

In the phase II DAWN study reported in the Journal of Clinical Oncology, Gopal et al found that ibrutinib (Imbruvica) produced a response in a minority of patients with relapsed or refractory follicular lymphoma. Study Details In the study, 110 patients with ≥ 2 prior lines of treatment...

leukemia

Suboptimal Use of Initial Chemotherapy in Newly Diagnosed AML

In a study of National Cancer Database data reported in Blood Advances, Bhatt et al found that 25% of patients with newly diagnosed acute myeloid leukemia (AML) did not receive initial chemotherapy, despite evidence that chemotherapy is associated with a survival benefit and improvement in symptoms ...

integrative oncology

Green Tea

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on the potential health benefits ...

hematologic malignancies

From Italy to Boston, A Love of Molecular Diagnostics Shapes a Career for Valentina Nardi, MD

Valentina Nardi, MD, is a staff pathologist at Massachusetts General Hospital, and her current clinical work includes implementing molecular assays for hematologic malignancies at the Center for Integrated Diagnostics. “I was born in Rome, but I did my high school and college education in Genoa. I ...

Steven A. Rosenberg, MD, PhD, Receives American College of Surgeons Jacobson Innovation Award

THE 2018 JACOBSON INNOVATION AWARD of the American College of Surgeons was recently presented to Steven A. Rosenberg, MD, PhD, Chief of the Surgery Branch at the National Cancer Institute (NCI) as well as Professor of Surgery at the Uniformed Services University of Health Sciences and at the...

palliative care

How Learning What’s on Your Patient’s Bucket List May Improve Care

It may sound too good to be true, but asking patients a simple question about what is on their bucket list can actually spark a dialogue about how best to make their cancer care and survivorship fit into their life plans, as well as be an effective way to identify their end-of-life care goals,...

ESMO Prioritizes Cancer Care at 71st World Health Assembly

AT THE 71ST World Health Assembly in Geneva, the European Society for Medical Oncology (ESMO) delivered two statements positioning cancer as a priority on the global agenda of the World Health Organization (WHO). Presenting its recommendations for action to the international community, ESMO...

issues in oncology
palliative care

Voluntarily Stopping Eating and Drinking Is Legal—and Ethical—for Terminally Ill Patients Looking to Hasten Death

Terminally ill patients with cancer will sometimes ask their clinicians for help with assisted or hastened death.1 Although palliative care and hospice care can usually address the concerns of most patients, some have physical or existential suffering that is refractory to comfort and supportive...

Meet Federal Reporting Requirements With QOPI® Reporting Registry

The QOPI® Reporting Registry, a Qualified Clinical Data Registry (QCDR) brought to you by ASCO and the American Society for Radiation Oncology (ASTRO), is your one-stop shop for 2018 Centers for Medicare and Medicaid Services (CMS) Merit-based Incentive Payment System (MIPS) reporting. The new...

leukemia

Patients With AML Have Reduced Risk of Early Mortality at NCI-Designated Cancer Centers

RESEARCHERS AT the University of California (UC), Davis, have shown that patients with acute myeloid leukemia (AML) who received their care at a National Cancer Institute (NCI) cancer center in California had a dramatically reduced risk of early mortality. Using data from the California Cancer...

Leave a Legacy of Hope

By including a planned gift to ASCO’s Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for patients with cancer years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: ...

Register Today for the ASCO Research Community Forum 2018 Annual Meeting

This year’s ASCO Research Community Forum (RCF) 2018 Annual Meeting will not be one to miss! Though still a few months away, I am thrilled to share the work that is already underway to bring the research community together for 2 days of learning and collaboration. During my term as Chair of the...

Updated: Cancer.Net Mobile App for Your Patients

Tell your patients about Cancer.Net’s award-winning mobile app! Recently updated, the newest version features several performance upgrades to improve the user experience, plus all the same great features offered before, including filtering capabilities, calendar integration, and native Spanish...

issues in oncology

Resilience While Caring for Seriously Ill Patients: Skills and Strategies to Prevent Burnout

A career in oncology can be extremely rewarding. Fast-paced advances in research and treatment, exciting changes in the practice environment, and the opportunity to build strong relationships with and provide critical support to patients can be incredibly professionally satisfying—but they can...

breast cancer

Expert Point of View: Julie Margenthaler, MD, FACS

JULIE MARGENTHALER, MD, FACS, a breast surgeon at Washington University School of Medicine and American Society of Breast Surgeons Communications Committee Chair, highlighted the importance of exploring clinical endpoints outside of a survival advantage.  “While numerous studies have shown the...

breast cancer

Regular Mammograms Linked to Less Aggressive Treatment in Patients With Breast Cancer

A STUDY evaluating the impact of breast cancer screening has shown that the benefits of regular mammograms extend well beyond reduced mortality. According to data presented at the American Society of Breast Surgeons (ASBrS) 2018 Annual Meeting, women with breast cancer who underwent regular...

breast cancer

AJCC Breast Cancer Staging System More Clinically Relevant

THE RECENTLY issued 8th revision to the American Joint Committee on Cancer (AJCC) Breast Cancer Staging System incorporates tumor biology and prognostic stage groups and thus has become more accurate and clinically relevant, according to two speakers at the 2018 Miami Breast Cancer Conference.1,2...

Folakemi Odedina, PhD, Awarded Fellowship for Oncology Clinical Trials in Africa

FOLAKEMI ODEDINA, PhD, Professor of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy, has been awarded a 2018 Carnegie African Diaspora Fellowship to help expand oncology clinical trials in Africa.  Dr. Odedina will travel to South Africa to collaborate...

Dan Theodorescu, MD, PhD, Appointed Director of Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai

DAN THEODORESCU, MD, PhD, has been named Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, a position he will assume starting July 1, 2018.  Dr. Theodorescu, a translational cancer researcher and expert in bladder cancer, will direct the oncology enterprise at...

Researchers Can Access Wide Array of ASCO Data Through CENTRA

Researchers can access a wide array of ASCO data through the Society’s Center for Research and Analytics (CENTRA). A detailed list of the data, along with samples of each data set, can be found on CENTRA’s updated data library page.  ASCO maintains an expansive repository of information that...

Be Counted—Complete the 2018 ASCO Practice Census Today

ASCO invites you to participate in the 2018 ASCO Practice Census. Just as you monitor the health of your patients, ASCO regularly gathers information on the oncology practice environment, and we need your help to do so. The ASCO Practice Census is an annual survey designed to capture comprehensive, ...

issues in oncology

Changes to Maintenance of Certification: New Pathways for Assessment

As you know, for more than 2 years, ASCO has been working closely with the American Board of Internal Medicine (ABIM) to shape the future of maintenance of certification (MOC) and assessment for our specialty. The ASCO MOC Task Force was charged by ASCO’s membership to make the process for...

solid tumors
prostate cancer

Prostate Cancer Therapy in Evolution: Time to Rethink and Redirect?

The ASCO updated guidelines on the treatment of metastatic non-castrate prostate cancer penned by Morris and his colleagues1 provide valuable information annotated to the strengths of evidence in recently reported prostate cancer studies. CHAARTED, GETUG-AFU 15, LATITUDE, and STAMPEDE have...

solid tumors
prostate cancer

De Novo Metastatic Prostate Cancer: Positive Recent News, Many Open Questions

After about 70 years with no significant progress, the landscape for men with de novo metastatic prostate cancer has changed dramatically in the past 4 years, with statistically significant and highly clinically meaningful survival improvement reported from multiple phase III trials when...

prostate cancer

DNA Test Identifies Men With Sixfold Increased Risk of Prostate Cancer

A major new study of more than 140,000 men has identified 63 new genetic variations in the DNA code that increase the risk of prostate cancer. These findings were published by Schumacher et al in Nature Genetics. Researchers devised a new test combining these single-letter genetic variants with...

issues in oncology

Parents See Cancer Prevention Potential as Best Reason for HPV Vaccination

Parents of adolescents believed that the potential to prevent certain types of cancer is the best reason for their children to receive the human papillomavirus (HPV) vaccine, whereas other reasons health-care providers often give were far less persuasive. Findings from this study were published by...

Journal of Oncology Practice Launches New Blog to Facilitate Discussions on Care Delivery Topics

The Journal of Oncology Practice (JOP) has launched a new care delivery blog, JOP DAiS (Discussion & Analysis in Short), to serve as a forum for commentary and analysis on issues affecting the mechanisms of oncology care delivery. This new platform will be a way to collaborate, debate, and...

breast cancer

ASCO/CAP Clinical Practice Guideline Focused Update on HER2 Testing in Breast Cancer

As reported in the Journal of Clinical Oncology by Antonio C. Wolff, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and colleagues, ASCO and the College of American Pathologists (CAP) have issued a clinical practice guideline focused update on HER2 testing in breast cancer....

solid tumors
prostate cancer

ASCO Clinical Practice Guideline: Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer

As reported in the Journal of Clinical Oncology by Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, and colleagues, ASCO has released a clinical practice guideline on optimizing anticancer therapy in men with metastatic non-castrate prostate cancer.1 To ...

Expert Point of View: Naiyer Rizvi, MD

“In CheckMate 227, the benefit of nivolumab [Opdivo] plus ipilimumab [Yervoy] was the same in tumor mutational burden–high patients whether or not they were programmed cell death ligand 1 (PD-L1)–high or –low,” said formal discussant of this paper, Naiyer Rizvi, MD, Director of Thoracic Oncology...

solid tumors
lung cancer

Nivolumab Plus Ipilimumab Improves Progression-Free Survival in NSCLC With High Tumor Mutational Burden

The combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved progression-free survival compared with chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) and a high tumor mutational burden irrespective of programmed cell death ligand 1...

Advertisement

Advertisement




Advertisement